About the PDMP

The Prescription Drug Monitoring Program (PDMP) aims to improve the District’s ability to identify and reduce diversion of prescription drugs in an efficient and cost effective manner that will not impede the appropriate medical utilization of controlled substances. The PDMP also aims to enhance patient care by providing prescription monitoring information that will assure legitimate use of controlled substances in health care, including palliative care, research and other medical and pharmacological uses.

PDMP Database Access

MANDATORY REGISTRATION: All licensed prescribers and dispensers must register for the DC Prescription Drug Monitoring Program. Read the notice to practitioners or FAQs about mandatory registration for full details.

For dispensers: As of June 7, 2019, gabapentin is a covered substance for the DC PDMP. Dispensers are required to report dispensations of gabapentin to the DC PDMP.

PMP AWAR_XE™ PMP AWAR_XE™ is the software platform that providers use to access the PDMP.

NarxCare The NarxCare platform allows providers and dispensers to view patient health history, patient risk scores, and their own quarterly provider reports. NarxCare's analytics tools help providers and dispensers make decisions to increase patient safety and reduce the risk of prescription drug misuse and overdose.

Gateway Integration  The DC PDMP provides the option to all Health Care Entitiies (HCE) in the District of Columbia to integrate DC PDMP data into their clinical workflow. Grant funding is available for integration of PDMP data into electronic health records (EHRs), health information exchanges (HIEs), and pharmacy management systems.

PDMP Advisory Committee The DC PDMP Advisory Comittee is a multisector committee made up of 7 members.The committee's goal is to make recommendations to DC Health's director regarding PDMP best practice, regulatory and legislative updates, education and outreach to prescribers and dispensers, and program enhancements.

In response to COVID-19, the District of Columbia Prescription Drug Advisory Committee meeting scheduled for April 21, 2020 is now CANCELED. If you have questions regarding the Coronavirus, please visit https://dchealth.dc.gov/page/health-notices and https://coronavirus.dc.gov/.

Additional Resources

• Prescription Drug Monitoring Program Law
• Prescription Drug Monitoring Program Final Rulemaking
• Notices
• Frequently Asked Questions
• Frequently Asked Questions for Mandatory Registration
• Guides
• Forms
• Annual Report

All questions and press inquiries regarding the Prescription Drug Monitoring Program must be submitted in writing. Interested parties may send inquiries by email to [email protected] or by regular mail to:

Prescription Drug Monitoring Program 
Health Regulation and Licensing Administration
899 N. Capitol Street, NE
2nd Floor
Washington, DC 20002